Qiagen (NYSE:QGEN) Sees Strong Trading Volume – Should You Buy?

Qiagen N.V. (NYSE:QGEN) saw an uptick in trading volume on Tuesday . 1,621,031 shares were traded during mid-day trading, a decline of 27% from the previous session’s volume of 2,216,468 shares.The stock last traded at $34.1250 and had previously closed at $38.09.

Analysts Set New Price Targets

A number of brokerages have weighed in on QGEN. Deutsche Bank Aktiengesellschaft raised Qiagen from a “hold” rating to a “buy” rating and set a $54.00 price objective on the stock in a report on Friday, March 13th. Wall Street Zen cut shares of Qiagen from a “buy” rating to a “hold” rating in a research note on Saturday, March 28th. Zacks Research cut shares of Qiagen from a “hold” rating to a “strong sell” rating in a research note on Monday, March 9th. Citigroup lowered their price target on shares of Qiagen from $55.40 to $55.00 and set a “neutral” rating on the stock in a research note on Friday, February 6th. Finally, Barclays set a $44.00 price target on shares of Qiagen and gave the stock an “equal weight” rating in a research note on Tuesday, April 14th. Four investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $53.64.

Qiagen Stock Down 10.5%

The stock has a market capitalization of $7.02 billion, a PE ratio of 16.89, a P/E/G ratio of 1.99 and a beta of 0.79. The firm has a 50 day moving average of $42.66 and a two-hundred day moving average of $47.06. The company has a current ratio of 3.90, a quick ratio of 3.31 and a debt-to-equity ratio of 0.44.

Qiagen (NYSE:QGEN) last released its quarterly earnings data on Wednesday, February 4th. The company reported $0.62 earnings per share for the quarter, beating the consensus estimate of $0.61 by $0.01. Qiagen had a return on equity of 14.56% and a net margin of 20.33%.The firm had revenue of $540.42 million during the quarter, compared to the consensus estimate of $528.53 million. During the same period last year, the business posted $0.61 EPS. Qiagen’s quarterly revenue was up 3.6% on a year-over-year basis. Qiagen has set its FY 2026 guidance at 2.500- EPS and its Q1 2026 guidance at 0.540- EPS. Equities research analysts anticipate that Qiagen N.V. will post 2.5 earnings per share for the current year.

Hedge Funds Weigh In On Qiagen

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in QGEN. Danske Bank A S purchased a new stake in shares of Qiagen in the third quarter valued at $36,000. Smartleaf Asset Management LLC lifted its position in shares of Qiagen by 1,383.3% in the third quarter. Smartleaf Asset Management LLC now owns 890 shares of the company’s stock valued at $39,000 after acquiring an additional 830 shares in the last quarter. Manchester Capital Management LLC purchased a new stake in shares of Qiagen in the fourth quarter valued at $42,000. Global Retirement Partners LLC lifted its position in shares of Qiagen by 279.9% in the fourth quarter. Global Retirement Partners LLC now owns 1,155 shares of the company’s stock valued at $52,000 after acquiring an additional 851 shares in the last quarter. Finally, Allworth Financial LP lifted its position in shares of Qiagen by 23.2% in the third quarter. Allworth Financial LP now owns 1,358 shares of the company’s stock valued at $61,000 after acquiring an additional 256 shares in the last quarter. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library‐preparation kits and proteomics solutions.